Comparative Pharmacology
Head-to-head clinical analysis: EDARBYCLOR versus HYDROMOX R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDARBYCLOR versus HYDROMOX R.
EDARBYCLOR vs HYDROMOX R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Thiazide-like diuretic that inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
Oral, 50 mg once daily, increased to 100 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30% as unchanged drug and metabolites.
Category C
Category C
Angiotensin II Receptor Blocker/Thiazide Diuretic Combination
Thiazide Diuretic Combination